Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Vertex Pharmaceuticals Stock Jumps
Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.
US FDA approves Vertex's non-opioid painkiller
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator said on Thursday, offering a first-of-its-kind alternative to addictive opioid painkillers that have fueled a national crisis.
England, Vertex Pharmaceuticals and Sickle Cell Disease
Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England
Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to treat sickle cell disease. Read more here.
Vertex In CASGEVY Reimbursement Deal With NHS England For Sickle Cell Disease Patients
Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY ® (exagamglogene autotemcel).
1h
Vertex Pharmaceuticals price target raised to $545 from $520 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
1h
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Black boxes recovered
Los Angeles wildfire updates
Cause of death revealed
Apologizes for old tweets
Activists call for boycott
Granted legal personhood
Michigan priest loses license
Sexual misconduct accusation
Inmate's transfer blocked
Top leaders asked to resign
Asteroid may hit Earth
To raise hourly pay
Recuses self from Act 10 suit
Ex-worker admits to theft
Olympic gold medalist dies
2 more victims in indictment
'As Tears Go By' singer dies
Confirmed interior secretary
US inflation ticked higher
Hamas confirms death
Searching for joyriders
S3 release date revealed
Deputy shooting sentence
Blames DEI for crash
FDA approves painkiller
Ground stop amid IT outage
DOJ sues to block deal
Nashville bids for franchise
Partners w/ US national labs
Related topics
Journavx
Non-Opioid Painkiller
Apple
Trade
Food and Drug Administration
Feedback